South Korea has published its latest official healthcare workforce survey, providing a new government benchmark for physician remuneration and working conditions across the country's healthcare system. Full-time physicians working in South Korean healthcare institutions earned average annual remuneration of ₩285.18 million, according to the latest official physician compensation data published by the Ministry of Health and Welfare. South Korea's latest government data provide a new benchmark for physician compensation, revealing substantial differences in average remuneration according to the type of healthcare institution in which doctors work. Full-time physicians working in healthcare institutions received average annual remuneration of ₩285.18 million, equivalent to approximately ₩23.77 million per month when divided across 12 months. The figures come from the Ministry of Health and Welfare's Second Healthcare Workforce Conditions Survey, published on 29 September 2026. The underlying remuneration data relate to 2023, making them the latest official government figures rather than a measure of earnings during 2026. Key findings Average annual physician remuneration: ₩285.18 million Approximate monthly equivalent: ₩23.77 million Hospitals: ₩354.27 million Clinics: ₩325.99 million General hospitals: ₩251.45 million Tertiary general hospitals: ₩199.76 million Doctors working at least 40 hours per week were included Interns and residents were excluded Remuneration was based on salary information used for National Health Insurance contributions The remuneration figures relate to 2023, with the official survey results published in September 2026 Average physician remuneration reaches ₩285.18 million The Ministry reports average annual remuneration of ₩285.18 million among physicians working full-time in healthcare institutions. That equates to approximately ₩23.77 million per month, although the Ministry's measure is annual remuneration rather than a monthly salary benchmark. The survey includes doctors working at least 40 hours per week while excluding interns and residents, providing a benchmark focused on the established physician workforce. Unlike compensation surveys based on doctors voluntarily reporting their earnings, the Ministry's remuneration measure uses the monthly remuneration base employed in calculating National Health Insurance contributions. It should therefore be understood as recorded employment remuneration rather than a measure of every potential source of professional income available to a physician. Physician remuneration varies substantially by institution One of the most notable findings is the difference in physician remuneration between different types of healthcare institutions. Physicians working in hospitals recorded the highest average annual remuneration at ₩354.27 million. This was followed by: Clinics: ₩325.99 million General hospitals: ₩251.45 million Tertiary general hospitals: ₩199.76 million The difference between the highest and lowest institutional averages was substantial. Average physician remuneration in hospitals was approximately ₩154.51 million higher than in tertiary general hospitals. On this measure, the hospital average was approximately 77% higher than the tertiary-general-hospital average. Why do institution-level differences matter? The figures demonstrate why a single national average cannot describe the compensation of every South Korean physician. The type of healthcare institution in which a doctor works is associated with substantially different average remuneration levels in the Ministry's data. However, the figures should not be interpreted as demonstrating that the institution type itself causes the difference. Factors such as physician characteristics, working arrangements, specialty mix, seniority and the structure of medical activity within different types of healthcare organisations may contribute to the variation. The institution-level figures are therefore most useful as national compensation benchmarks rather than expected salaries for individual doctors. What does the latest figure mean for South Korean physicians? The ₩285.18 million annual average provides a new official benchmark for assessing physician remuneration in South Korea. The underlying methodology also makes the findings particularly valuable for compensation research. Rather than relying on advertised salaries or self-reported estimates, the remuneration measure is based on salary information used to calculate National Health Insurance contributions. There are nevertheless important limitations. The figures do not provide individual specialty benchmarks for areas such as cardiology, oncology or dermatology, and they should not be interpreted as capturing every possible source of physician professional income. They also represent average rather than median remuneration, meaning the figures do not indicate what the physician at the midpoint of the earnings distribution received. Latest release, but 2023 remuneration The timing of the data is important when interpreting the findings. The Ministry published its Second Healthcare Workforce Conditions Survey on 29 September 2026, but the physician remuneration figures relate to 2023. The figures should therefore not be described as what South Korean physicians "earn in 2026". Instead, they represent the latest official physician remuneration data available from the South Korean government as of 2026. This distinction is particularly important when comparing physician compensation internationally, as official healthcare workforce datasets are often released considerably later than the period to which the earnings data relate. About the data South Korea's Ministry of Health and Welfare published the Second Healthcare Workforce Conditions Survey on 29 September 2026. For physician remuneration, the survey uses the monthly remuneration base applied to National Health Insurance contributions. The reported figures cover doctors working at least 40 hours per week in healthcare institutions and exclude interns and residents. The remuneration figures relate to 2023. Source Ministry of Health and Welfare, Republic of Korea. Second Healthcare Workforce Conditions Survey. Published 29 September 2026.https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&tag=&act=view&list_no=1492074&cg_code= Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Novotech has agreed to acquire Agilex Biolabs, adding specialist bioanalytical laboratory capabilities to its Australian clinical-development platform. Agilex provides bioanalytical services supporting early-stage drug development and will broaden Novotech's ability to offer integrated laboratory and clinical services. The acquisition strengthens Novotech's early-phase infrastructure in Australia and expands the range of services available to biotechnology and pharmaceutical sponsors. Field Content Article Type Deals Companies Novotech; Agilex Biolabs Deal Type Acquisition Acquired Company Agilex Biolabs Sector Contract research organisation and bioanalytical services Capabilities Bioanalysis; early-phase drug development support; laboratory services Geography Australia What Happened Novotech agreed to acquire Adelaide-based Agilex Biolabs. Why It Matters The transaction adds specialist bioanalytical laboratory capabilities to Novotech's existing clinical-development infrastructure. Supporting Context Agilex supports pharmaceutical and biotechnology clients with bioanalytical services used during early drug development. Strategic Rationale The acquisition enables Novotech to provide a more integrated clinical and laboratory offering to sponsors. Potential Impact Clients may be able to consolidate more early-phase clinical and bioanalytical work within a single service provider. Key Takeaway Novotech is expanding its Australian early-development platform through the acquisition of Agilex Biolabs. What to Watch Transaction completion, integration of Agilex capabilities and expansion of combined laboratory services. Primary Source Novotech Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sanofi and Regeneron have expanded their long-running immunology alliance with four next-generation antibody programmes in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront and could earn up to $7 billion in additional development, regulatory and commercial milestone payments. The expanded partnership includes long-acting IL-13 and IL-4/IL-13 programmes and retains an equal sharing model for development costs, commercialisation costs and future profits. Field Content Article Type Deals Companies Sanofi; Regeneron Deal Type Expanded global immunology research and development alliance Therapy Area Immunology Programme Scope Four next-generation long-acting antibody programmes Key Assets REGN20423; long-acting IL-4xIL-13 bispecific and additional antibody programmes Technology/Modality Monoclonal and bispecific antibodies Upfront Payment $1 billion Potential Milestones Up to $7 billion Potential Deal Value Up to $8 billion Economics Development and commercialisation costs and future profits shared equally What Happened Sanofi and Regeneron expanded their longstanding immunology alliance to include four next-generation antibody programmes. Why It Matters The transaction extends one of biopharma's most established immunology partnerships into additional long-acting programmes intended to build on the companies' experience with Dupixent. Strategic Rationale Sanofi and Regeneron are combining their immunology development capabilities to create longer-acting and potentially differentiated therapies across inflammatory diseases. Potential Impact Successful programmes could expand the companies' presence across major immunology indications and create successors or complements to existing therapies. Key Takeaway Sanofi and Regeneron have expanded their immunology alliance in a transaction worth up to $8 billion. What to Watch Clinical progression of REGN20423, development of the IL-4xIL-13 bispecific and disclosure of the remaining programmes. Primary Source Regeneron Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates. The initial assets are SB41, a proposed biosimilar to Fasenra, and SB44, a proposed biosimilar to Ilaris, with Samsung Bioepis leading development and manufacturing. Teva will contribute commercial capabilities across the US, Europe and Canada, creating a multi-product platform spanning major immunology and inflammatory-disease markets. Field Content Article Type Deals Companies Samsung Bioepis; Teva Pharmaceuticals Deal Type Strategic biosimilars development and commercialisation partnership Initial Assets SB41; SB44 Reference Products Fasenra; Ilaris Programme Scope Two named biosimilars plus options for up to four additional candidates Therapy Areas Immunology; inflammatory disease Technology/Modality Monoclonal antibody biosimilars Development Responsibilities Samsung Bioepis will lead development, regulatory activities and manufacturing Commercial Responsibilities Teva will contribute commercial infrastructure in agreed markets Core Markets United States; Europe; Canada What Happened Samsung Bioepis and Teva expanded their strategic partnership to cover up to six potential biosimilar candidates. Why It Matters The agreement creates a sizeable multi-asset biosimilars collaboration spanning major biologic markets and multiple geographies. Strategic Rationale Samsung Bioepis contributes biosimilar development and manufacturing expertise while Teva provides established commercial infrastructure. Potential Impact The partnership could increase biosimilar competition across high-value immunology and inflammatory-disease products. Key Takeaway Samsung Bioepis and Teva are building a biosimilars portfolio of up to six candidates, starting with proposed Fasenra and Ilaris biosimilars. What to Watch Regulatory development of SB41 and SB44 and selection of the four optional additional candidates. Primary Source Samsung Bioepis Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

SpyGlass Pharma has acquired Advanced Vision Science for approximately $13 million, bringing manufacturing of a key intraocular lens used in its drug-delivery platform in-house. The acquired business manufactures the intraocular lens used in SpyGlass' Phase III BIM-IOL System, which is being developed as a sustained ophthalmic drug-delivery platform. The acquisition gives SpyGlass direct control over an important manufacturing capability as it prepares for potential commercialisation and future expansion of the platform. Field Content Article Type Deals Companies SpyGlass Pharma; Advanced Vision Science; Santen Deal Type Acquisition Transaction Value Approximately $13 million in cash Acquired Company Advanced Vision Science Therapy Area Ophthalmology Technology/Modality Intraocular lens manufacturing and sustained ophthalmic drug delivery Key Programme BIM-IOL System Development Stage Phase III What Happened SpyGlass Pharma acquired 100% of Advanced Vision Science from Santen for approximately $13 million in cash. Why It Matters Advanced Vision Science manufactures the intraocular lens used in SpyGlass' Phase III BIM-IOL System, making the acquisition strategically important to future supply and commercialisation. Strategic Rationale Owning the manufacturing capability gives SpyGlass greater control over production, scale-up and potential commercial supply. Potential Impact The transaction could reduce supply-chain dependence and support expansion of SpyGlass' ophthalmic drug-delivery platform. Key Takeaway SpyGlass has acquired a critical intraocular-lens manufacturing business supporting its Phase III ophthalmology platform. What to Watch Integration of AVS, Phase III progress for BIM-IOL and commercial manufacturing scale-up. Primary Source SpyGlass Pharma Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved the first surgically implanted heart valve designed to be enlarged as a child grows, potentially reducing the need for repeat operations. The Autus Size-Adjustable Valve is approved for paediatric patients with congenital pulmonary valve disease and can be expanded later using a balloon catheter. It is also the first US-approved heart valve to use polymeric rather than animal-derived leaflets, introducing a new approach to long-term paediatric valve replacement. Field Content Article Type Approvals Product Autus Size-Adjustable Valve Regulatory Authority U.S. Food and Drug Administration Approval Type Medical device approval Indication Paediatric patients with congenital pulmonary valve disease requiring surgical pulmonary valve replacement Patient Population Children with congenital pulmonary valve disease Therapy Area Cardiology; congenital heart disease; paediatric cardiology Technology/Modality Size-adjustable surgically implanted pulmonary heart valve Valve Material Polymeric leaflets Geography United States What Happened The FDA approved the Autus Size-Adjustable Valve for paediatric pulmonary valve replacement. Why It Matters The valve can be enlarged using a balloon catheter as a child grows, potentially reducing the need for repeated open-heart surgery. Supporting Context The device is also the first US-approved heart valve to use polymeric rather than animal-derived leaflets. Potential Impact The technology may reduce lifetime surgical burden for children who would otherwise outgrow fixed-size replacement valves. Key Takeaway The Autus valve is the first FDA-approved heart valve designed to grow with paediatric patients. What to Watch Clinical adoption, long-term durability and real-world evidence on avoidance of repeat surgery. Primary Source U.S. Food and Drug Administration Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Average annual salaries across China's health and social work sector increased in 2025, with employees in urban non-private organisations earning almost twice the average recorded in private organisations, according to new official data. China's National Bureau of Statistics has published its latest annual wage data, providing a new benchmark for compensation across the country's healthcare and social work sector. Employees in urban non-private health and social work organisations earned an average RMB 146,266 in 2025, compared with RMB 143,173 in 2024. Average annual compensation in urban private health and social work organisations was considerably lower at RMB 75,631, compared with RMB 75,287 in 2024. The figures provide a useful indication of compensation trends within China's healthcare workforce, although they cover the broader health and social work sector and should not be interpreted as physician-specific salaries. Key findings Average annual salary in urban non-private health and social work organisations: RMB 146,266 2024 equivalent: RMB 143,173 Nominal annual increase: 2.2% Average annual salary in urban private health and social work organisations: RMB 75,631 2024 equivalent: RMB 75,287 Nominal annual increase: 0.5% The figures cover the wider health and social work sector, rather than physicians or individual medical specialties Healthcare compensation reaches RMB 146,266 in non-private organisations Average annual compensation for employees working in urban non-private health and social work organisations reached RMB 146,266 in 2025. That represents a nominal increase of 2.2% compared with the RMB 143,173 recorded a year earlier. The sector's average was also above the RMB 129,441 average across all urban non-private organisations included in the statistics. This means average compensation in the health and social work category was approximately 13% above the overall non-private urban workforce average. Private healthcare compensation shows slower growth The picture was different among private organisations. Employees in urban private health and social work organisations earned an average RMB 75,631 in 2025, representing nominal growth of just 0.5% from RMB 75,287 in 2024. The overall average across China's urban private-sector organisations was RMB 71,590. Health and social work compensation was therefore approximately 6% above the overall private-sector average. Significant difference between private and non-private averages The data also highlights a substantial difference between the two employment categories. The RMB 146,266 average recorded in non-private health and social work organisations was approximately 93% higher than the RMB 75,631 average recorded among private organisations. However, this should not automatically be interpreted as evidence that equivalent healthcare roles receive almost twice the salary in non-private organisations. The two datasets cover different groups of employers and employees, and differences in workforce composition, occupations and organisational structures can influence their respective averages. What do the figures tell us about doctors' salaries in China? The data provides an authoritative national benchmark for China's healthcare labour market, but it has an important limitation when considering physician compensation. The National Bureau of Statistics groups healthcare together with social work and does not provide a separate physician salary figure within these particular tables. The averages therefore include employees across a much broader workforce and cannot be used to state that the average Chinese doctor earns RMB 146,266 or RMB 75,631 per year. For physician compensation research, the figures are more appropriately treated as a national healthcare-sector benchmark against which more detailed physician and specialty-level salary evidence can subsequently be assessed. About the data The National Bureau of Statistics published the figures on 15 May 2026, covering average wages during 2025. Average wages are calculated using the total wages paid by organisations divided by their average number of employees during the reporting period. The wage measure is pre-tax and includes amounts deducted or withheld for individual income tax, employees' social insurance contributions and housing provident fund contributions. The wider urban employment survey covered approximately 3.062 million organisations in 2025. Self-employed individuals and freelancers are not included. Source National Bureau of Statistics of China. Average Annual Wages of Employees in Urban Units in 2025.https://www.stats.gov.cn/sj/zxfb/202605/t20260515_1963707.html Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

New 2026 compensation data provides a snapshot of physician salaries across medical specialties in Brazil, highlighting significant differences in formal employment pay and the importance of looking beyond base salary when assessing doctors’ total earnings. Physician compensation in Brazil varies according to specialty, working hours, location and employment model, with many doctors combining formal employment with shifts, private consultations or additional roles. A 2026 analysis published by Afya Educação Médica provides salary benchmarks across a range of medical specialties, drawing primarily on formal employment data. The figures offer an indication of what doctors can earn within Brazil's CLT employment market, while also demonstrating why base salary alone does not necessarily represent a physician's total income. Physician salaries in Brazil in 2026 Afya's analysis presents compensation benchmarks across numerous specialties, including: Cardiology Pediatrics Obstetrics & Gynecology General Surgery Internal Medicine Occupational Medicine Orthopaedics & Traumatology Ophthalmology Radiology Psychiatry Dermatology Otolaryngology Plastic Surgery Intensive Care Medicine One example is cardiology, where the analysis reports average compensation of approximately R$8,434 per month for an average working week of around 22 hours. However, comparisons between specialties need to account for differences in contracted hours as well as the different ways physicians work. Base salary does not tell the whole story A particularly important feature of Brazilian physician compensation is the distinction between formal salary and total professional income. The specialty figures highlighted by Afya principally reflect base salaries associated with formal CLT employment. They therefore do not necessarily capture income doctors may receive from additional hospital shifts, private consultations, independent practice or simultaneous employment relationships. A physician's actual monthly earnings can consequently be considerably different from the salary associated with an individual formal position. Additional shifts can significantly affect physician earnings Medical shifts represent another important component of physician compensation in Brazil. Afya cites a 2026 reference value from the Federação Nacional dos Médicos (FENAM) of R$3,168.38 for a 12-hour medical shift. Actual shift payments can differ according to factors including specialty, region, healthcare organisation and demand for medical professionals. For doctors undertaking several additional shifts during a month, this creates an income stream that would not be reflected in their formal base salary. Location and employment model matter Geography can also influence physician compensation. Pay opportunities can differ between Brazilian states and cities according to the supply of specialists, local demand, healthcare infrastructure and employment conditions. The type of work undertaken is similarly important. Physicians may work across public healthcare services, private hospitals, clinics and independent practice, potentially combining several sources of income. As a result, two physicians in the same specialty can have substantially different overall earnings despite having similar formal salary arrangements. Brazil's 2026 physician salary reference Alongside observed salary data, Afya highlights the 2026 FENAM reference salary floor of R$21,122.56 for a 20-hour working week. This figure should be distinguished from observed average salaries in formal employment. It is a reference benchmark rather than an indication that every physician employed in Brazil receives this amount. The difference illustrates why physician compensation data needs to be interpreted according to its underlying methodology, employment arrangement and working hours. What the 2026 figures mean for physicians The latest figures provide useful benchmarks for understanding physician compensation in Brazil, but no single salary figure can adequately describe what Brazilian doctors earn. Specialty is one factor, but working hours, additional shifts, private practice, geography and employment arrangements can all affect total compensation. For physicians assessing employment opportunities — and organisations benchmarking the Brazilian medical workforce — the most useful distinction is therefore between base salary for an individual position and total professional earnings across all medical activity. About the data Afya Educação Médica published its analysis of Brazilian medical salaries in July 2026. The specialty salary benchmarks reference data available through Portal Salário, which uses Brazilian employment information including Novo CAGED, eSocial and Empregador Web. These figures principally represent formal CLT employment and should not be interpreted as comprehensive estimates of total physician income. Source Afya Educação Médica. Salário médico por especialidade: análise e mercado 2026.https://educacaomedica.afya.com.br/blog/salario-dos-medicos-especialistas Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission. Gazyva (obinutuzumab) reduced relapse risk in the Phase III INShore study, with 95% of treated patients experiencing no relapse after week eight and remaining in complete remission at one year. The approval introduces a B-cell-targeted therapy into a paediatric and adult nephrology setting where repeated relapses and prolonged immunosuppression can create substantial treatment burden. Field Content Article Type Approvals Drug Name Obinutuzumab Brand Name Gazyva Company Roche / Genentech Regulatory Authority U.S. Food and Drug Administration Approval Type New indication approval Indication Frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome in patients in complete remission Patient Population Adults and children aged two years and older Therapy Areas Nephrology; rare disease; paediatrics Technology/Modality Anti-CD20 monoclonal antibody Clinical Study Phase III INShore Key Result 95% of Gazyva-treated patients experienced no relapse after week eight and were in complete remission at one year, compared with 73% receiving mycophenolate mofetil Geography United States What Happened The FDA approved Gazyva to reduce relapse risk in eligible patients with childhood-onset idiopathic nephrotic syndrome. Why It Matters The approval provides a new B-cell-directed option for patients with frequently relapsing or steroid-dependent disease. Supporting Context Relapsing nephrotic syndrome can require repeated corticosteroid or immunosuppressive treatment, creating significant long-term treatment burden. Potential Impact Gazyva may help prolong remission and reduce relapse frequency in eligible patients. Key Takeaway Gazyva is now FDA approved for frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome from age two. What to Watch Treatment uptake, durability of remission and positioning relative to existing immunosuppressive strategies. Primary Source U.S. Food and Drug Administration Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has expanded Camzyos approval to paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy who weigh at least 30kg. Camzyos (mavacamten) is now approved to improve functional capacity and symptoms in both adults and eligible paediatric patients with obstructive hypertrophic cardiomyopathy. The expansion, supported by the Phase III SCOUT-HCM study, extends cardiac myosin inhibition into a younger patient population with this inherited heart condition. Field Content Article Type Approvals Drug Name Mavacamten Brand Name Camzyos Company Bristol Myers Squibb Regulatory Authority U.S. Food and Drug Administration Approval Type Indication expansion Indication Symptomatic obstructive hypertrophic cardiomyopathy Patient Population Adults and paediatric patients weighing at least 30kg Therapy Areas Cardiology; hypertrophic cardiomyopathy Technology/Modality Cardiac myosin inhibitor Clinical Study Phase III SCOUT-HCM Geography United States What Happened The FDA expanded Camzyos approval to eligible paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. Why It Matters The decision extends a disease-specific therapy for oHCM into a paediatric population with limited targeted treatment options. Supporting Context Bristol Myers Squibb describes Camzyos as the only FDA-approved therapy for oHCM in a paediatric population. Potential Impact The label expansion broadens access to cardiac myosin inhibition for younger patients meeting the weight and disease criteria. Key Takeaway Camzyos is now FDA approved for symptomatic oHCM in adults and eligible paediatric patients. What to Watch Paediatric uptake, guideline integration and longer-term safety and effectiveness data from younger patients. Primary Source Bristol Myers Squibb Relevant Date 30 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

ALK is investing approximately DKK 500 million to expand its long-term manufacturing partnership with Catalent and increase capacity for fast-dissolving allergy immunotherapy tablets. The three-year investment programme is expected to add around 300 million tablets of annual capacity, taking potential production to approximately 1.1 billion tablets from the early 2030s. The expanded partnership also secures long-term access to Catalent's Zydis technology and could support future peanut and tree-nut allergy tablet programmes. Field Content Article Type Deals Companies ALK; Catalent Deal Type Strategic manufacturing partnership expansion Investment Approximately DKK 500 million over three years Technology/Platform Catalent Zydis fast-dissolving tablet technology Therapy Areas Allergy; immunotherapy Manufacturing Scope Allergy immunotherapy tablets Additional Annual Capacity Approximately 300 million tablets Expected Total Annual Capacity Approximately 1.1 billion tablets from the early 2030s Potential Future Programmes Peanut and tree-nut allergy tablets What Happened ALK expanded its manufacturing partnership with Catalent through a DKK 500 million investment programme. Why It Matters The agreement materially increases production capacity for ALK's tablet-based allergy immunotherapy portfolio and secures long-term access to a specialised drug-delivery platform. Supporting Context Catalent's Zydis technology is used for rapidly dissolving oral tablets and forms part of ALK's existing allergy tablet manufacturing network. Strategic Rationale ALK is expanding capacity ahead of anticipated long-term demand and potential launches in additional allergy indications. Potential Impact Higher capacity could support wider global access to allergy immunotherapy tablets and future expansion into food-allergy treatment. Key Takeaway ALK is committing around DKK 500 million to increase annual allergy-tablet capacity to approximately 1.1 billion units. What to Watch Capacity build-out, future product launches and development of peanut and tree-nut allergy tablets. Primary Source ALK Relevant Date 30 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Medscape's 2026 Canada physician compensation report shows average total physician compensation of C$394,000, while fewer than half of respondents say they feel fairly paid. Average base salary was reported at C$290,000, with the survey also highlighting unpaid work and continuing financial pressure across the Canadian medical workforce. The findings provide a current benchmark for physician earnings, perceived compensation fairness and the wider economics affecting medical practice in Canada. Field Content Article Type Compensation Report Medscape Canada Physician Compensation Report 2026 Geography Canada Average Total Compensation C$394,000 Average Base Salary C$290,000 Fairly Compensated 47% of respondents Topic Physician compensation and workforce economics What Happened Medscape published its 2026 Canadian physician compensation report with new data on earnings and perceptions of pay. Why It Matters The report provides a current benchmark for physician remuneration while highlighting ongoing dissatisfaction with compensation and the burden of unpaid work. Supporting Context Less than half of surveyed physicians said they felt fairly compensated despite average total compensation approaching C$400,000. Workforce Context The findings sit within broader concerns around physician workload, practice costs and recruitment and retention pressures. Potential Impact Compensation trends can influence specialty choice, workforce mobility, recruitment and long-term health-system staffing. Key Takeaway Canadian physicians reported average total compensation of C$394,000, but only 47% said they felt fairly compensated. What to Watch Specialty-level pay differences, gender gaps, changes in unpaid workload and future compensation trends. Primary Source Medscape Relevant Date 29 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com